Tryptamine Therapeutics Limited (ASX:TYP)
Australia · Delayed Price · Currency is AUD 0.0310
-0.0010 (-3.13%)
At close: Sep 9, 2025
Tryptamine Therapeutics Revenue
In the fiscal year ending June 30, 2025, Tryptamine Therapeutics had annual revenue of 1.58M AUD with 19.17% growth. Tryptamine Therapeutics had revenue of 790.84K in the quarter ending June 30, 2025.
Revenue
1.58M
Revenue Growth
+19.17%
P/S Ratio
27.31
Revenue / Employee
n/a
Employees
n/a
Market Cap
43.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.58M | 254.43K | 19.17% |
| Jun 30, 2024 | 1.33M | - | - |
| Aug 31, 2023 | - | - | - |
| Aug 31, 2022 | - | - | - |
| Aug 31, 2021 | - | - | - |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 23.73B |
| Pro Medicus | 212.98M |
| Cochlear | 2.34B |
| Sonic Healthcare | 9.65B |
| Ramsay Health Care | 17.79B |
| Ansell | 3.06B |
| Telix Pharmaceuticals | 1.01B |
| Mesoblast | 26.23M |